Gil I. Wolfe

University at Buffalo, State University of New York — United States

Medicine · Health Sciences

53h-index13.4kcitations230works5.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myasthenia Gravis and Thymoma(130), Peripheral Neuropathies and Disorders(85), Parkinson's Disease and Spinal Disorders(65), Hereditary Neurological Disorders(21), Botulinum Toxin and Related Neurological Disorders(16)

Publications222 total

Urinary dysfunction in myasthenia Gravis: a cross-sectional case-control study
Neurological Sciences·2026Open Access
Ocular myasthenia gravis management
Frontiers in Neurology·2025Open Access
Reply to the Letter to the Editor: The Role of Patient‐Reported Symptoms in Standardizing <scp>MGFA</scp> Class 0 and <scp>MGFA</scp> ‐ <scp>PIS</scp>
Muscle & Nerve·2025
Pattern Recognition Approach to Neuropathy and Neuronopathy
Neurologic Clinics·2025
Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis
Journal of the Neurological Sciences·2025· 6 citedOpen Access
Myasthenia Gravis — Redemption for B-Cell Depletion
New England Journal of Medicine·2025· 1 cited
D.6 Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with Myasthenia Gravis
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques·2025Open Access
A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity
Frontiers in Public Health·2025· 1 citedOpen Access
Standardization of Myasthenia Gravis Outcome Measures in Clinical Practice: A Report of the <scp>MGFA</scp> Task Force
Muscle & Nerve·2025· 11 citedOpen Access
Changes in Nonsteroidal Immunosuppressive Treatment Usage Before and After Efgartigimod Initiation in Patients with Myasthenia Gravis (P1-11.015)
Neurology·2025
Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis (P1-11.033)
Neurology·2025
Hospitalization Outcomes After Efgartigimod Initiation in Patients with Myasthenia Gravis (P1-11.011)
Neurology·2025
Evaluation of Measures for Ocular Manifestations in Myasthenia Gravis (P1-11.002)
Neurology·2025
Neuromuscular Junction Disorders
RRNMF Neuromuscular Journal·2025Open Access
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
The Lancet Neurology·2025· 27 citedOpen Access
National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel
Therapeutic Advances in Neurological Disorders·2025· 3 citedOpen Access
Effect of Dental Liners' Elasticity on Cuspal-Deflection of Restorations
Dental Materials·2025
Myasthenia gravis: The evolving therapeutic landscape
eNeurologicalSci·2024· 6 citedOpen Access
Risk–Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis
Advances in Therapy·2024· 13 citedOpen Access
Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets
Journal of the Neurological Sciences·2024· 5 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Sharon Nations(13), Henry J. Kaminski(12), Wilson W. Bryan(12), Richard J. Barohn(12), Richard J. Barohn(11), Michael Benatar(10), Donald B. Sanders(9), Janice M. Massey(7), Carlayne E. Jackson(7), John T. Kissel(7), Gary Cutter(7), Nicholas J. Silvestri(7), Amelia Evoli(6), Anthony A. Amato(6), Michael Nicolle(5), Inmaculada Aban(5), Joël Oger(5), Tahseen Mozaffar(5), Alfred Jaretzki(5), John Newsom–Davis(5)